Lead Product(s): DM199
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DM199
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
DM199 is a recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1). DiaMedica plans to submit an investigational new drug (IND) application to the FDA for the phase 2/3 study in the first quarter of 2021.
Lead Product(s): Isoquercitrin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Quercis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2021
The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.